Philogen SpA (DE:78Q)

STUTTGART:78Q

78Q

Philogen SpA

RESEARCH TOOLSreports

Want to see DE:78Q full AI Analyst Report?

Philogen SpA (78Q) Price & Analysis

Q: What was Philogen SpA’s price range in the past 12 months?

Philogen SpA lowest stock price was €18.86 and its highest was €28.00 in the past 12 months.

Q: What is Philogen SpA’s market cap?

Philogen SpA’s market cap is €608.25M.

Q: When is Philogen SpA’s upcoming earnings report date?

Philogen SpA’s upcoming earnings report date is May 07, 2026 which is in 8 days.

Q: How were Philogen SpA’s earnings last quarter?

Philogen SpA released its earnings results on Apr 01, 2026. The company reported €6.07 earnings per share for the quarter, missing the consensus estimate of €7.62 by -€1.55.

Q: Is Philogen SpA overvalued?

According to Wall Street analysts Philogen SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Philogen SpA pay dividends?

Philogen SpA does not currently pay dividends.

Q: What is Philogen SpA’s EPS estimate?

Philogen SpA’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Philogen SpA have?

Philogen SpA has 29,242,860 shares outstanding.

Q: What happened to Philogen SpA’s price movement after its last earnings report?

Philogen SpA reported an EPS of €6.07 in its last earnings report, missing expectations of €7.62. Following the earnings report the stock price went up 0.444%.

Q: Which hedge fund is a major shareholder of Philogen SpA?

Currently, no hedge funds are holding shares in DE:78Q

0 Followers

78Q Stock Chart & Stats

€22.60

-€0.10(-0.54%)

At close: Jan 08 4:00 PM EST

€22.60

-€0.10(-0.54%)

Day’s Range― - ―

52-Week Range€18.86 - €28.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€608.25M

Enterprise Value€484.44M

Total Cash (Recent Filing)€100.02M

Total Debt (Recent Filing)€11.50M

Price to Earnings (P/E)4.1

Beta-0.15

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)6.07

Shares Outstanding29,242,860

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)2.51

Price to Sales (P/S)2.99

P/FCF Ratio3.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€26.00

Price Target Upside15.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€54.07M

Bulls Say, Bears Say

Bulls Say

Financial GrowthPhilogen anticipates tripling its revenues through its partnership agreement with Sun Pharma, indicating strong financial growth prospects.

Licensing AgreementPhilogen's global licensing agreement with RayzeBio for OncoACP3 boosts investor confidence in its innovation capabilities beyond existing products.

Bears Say

Market PerceptionAnalyst views Philogen's late-stage pipeline as underappreciated by the market, suggesting potential undervaluation of its stock.

Philogen SpA News

Philogen Continues Euronext Milan Share Buyback, Nears 0.9% Treasury Stake

Philogen SpA ( ($IT:PHIL) ) has shared an update. Philogen has continued to execute its share buyback programme...

2d ago

Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting

Philogen SpA ( ($IT:PHIL) ) has shared an announcement. Philogen S.p.A., the Italian-Swiss biotech group specializing in targeted...

9d ago

Philogen Adds to Treasury Stock as Biotech Group Advances Targeted Cancer Strategy

Philogen SpA ( ($IT:PHIL) ) has issued an update. Philogen S.p.A., the Italian-Swiss biotech group specializing in targeted...

9d ago

Philogen Expands Treasury Stock Position as Share Buyback Programme Progresses

Philogen SpA ( ($IT:PHIL) ) has shared an announcement. Philogen has continued its share buyback programme on Euronext...

16d ago

Philogen Publishes 2025 Financial and Governance Reports Ahead of April 2026 Shareholders’ Meeting

Philogen SpA ( ($IT:PHIL) ) has shared an update. Philogen S.p.A., a biotechnology group specializing in targeted anticancer...

21d ago

Philogen Discloses March Share Purchases by Mediobanca on Italian Market

The latest announcement is out from Philogen SpA ( ($IT:PHIL) ). Philogen S.p.A. disclosed that Mediobanca S.p.A., acting...

21d ago

Philogen Publishes Documentation Ahead of April 2026 Shareholders’ Meeting

An announcement from Philogen SpA ( ($IT:PHIL) ) is now available. Philogen S.p.A., an Italian-Swiss biotechnology group specializing...

30d ago

Philogen posts record 2025 profit on RayzeBio deal, plans dividend and R&D push

An announcement from Philogen SpA ( ($IT:PHIL) ) is now available. Philogen reported record 2025 results, with net...

1M ago

Philogen Expands Treasury Share Buyback, Nears 0.87% of Share Capital Held

Philogen SpA ( ($IT:PHIL) ) has shared an update. Philogen has provided an update on its ongoing treasury...

2M ago

Philogen Adds to Treasury Stock with Ongoing Share Buyback on Euronext Milan

Philogen SpA ( ($IT:PHIL) ) has issued an update. Philogen has reported fresh progress in its ongoing share...

2M ago

78Q FAQ

What was Philogen SpA’s price range in the past 12 months?

Philogen SpA lowest stock price was €18.86 and its highest was €28.00 in the past 12 months.

What is Philogen SpA’s market cap?

Philogen SpA’s market cap is €608.25M.

When is Philogen SpA’s upcoming earnings report date?

Philogen SpA’s upcoming earnings report date is May 07, 2026 which is in 8 days.

How were Philogen SpA’s earnings last quarter?

Philogen SpA released its earnings results on Apr 01, 2026. The company reported €6.07 earnings per share for the quarter, missing the consensus estimate of €7.62 by -€1.55.

Is Philogen SpA overvalued?

According to Wall Street analysts Philogen SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Philogen SpA pay dividends?

Philogen SpA does not currently pay dividends.

What is Philogen SpA’s EPS estimate?

Philogen SpA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Philogen SpA have?

Philogen SpA has 29,242,860 shares outstanding.

What happened to Philogen SpA’s price movement after its last earnings report?

Philogen SpA reported an EPS of €6.07 in its last earnings report, missing expectations of €7.62. Following the earnings report the stock price went up 0.444%.

Which hedge fund is a major shareholder of Philogen SpA?

Currently, no hedge funds are holding shares in DE:78Q

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Philogen SpA

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.

Philogen SpA (78Q) Earnings & Revenues

Historic Earnings Reports

78Q Stock 12 Month Forecast

Average Price Target

€26.00

▲(15.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"€17","26":"€26","35":"€35","21.5":"€21.5","30.5":"€30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.5,26,30.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.6,23.47692307692308,24.353846153846156,25.230769230769234,26.107692307692307,26.984615384615385,27.861538461538462,28.73846153846154,29.615384615384617,30.49230769230769,31.369230769230768,32.246153846153845,33.12307692307692,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.6,22.861538461538462,23.123076923076923,23.384615384615387,23.646153846153847,23.907692307692308,24.16923076923077,24.430769230769233,24.692307692307693,24.953846153846154,25.215384615384615,25.47692307692308,25.73846153846154,{"y":26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.6,22.24615384615385,21.892307692307693,21.53846153846154,21.184615384615384,20.83076923076923,20.47692307692308,20.123076923076923,19.76923076923077,19.415384615384617,19.06153846153846,18.70769230769231,18.353846153846153,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.1,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >